Ontology highlight
ABSTRACT:
SUBMITTER: Triulzi T
PROVIDER: S-EPMC9208076 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
Triulzi Tiziana T Bianchini Giampaolo G Di Cosimo Serena S Pienkowski Tadeusz T Im Young-Hyuck YH Bianchi Giulia Valeria GV Galbardi Barbara B Dugo Matteo M De Cecco Loris L Tseng Ling-Ming LM Liu Mei-Ching MC Bermejo Begoña B Semiglazov Vladimir V Viale Giulia G de la Haba-Rodriguez Juan J Oh Do-Youn DY Poirier Brigitte B Valagussa Pinuccia P Gianni Luca L Tagliabue Elda E
Molecular oncology 20211217 12
As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier trastuzumab advantage risk model (TRAR) as a predictive marker for patients enrolled in the NeoSphere trial. TRAR scores were computed from RNA of 350 pre- and 166 post-treatment tumor sp ...[more]